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A decade ago a hypothesis was proposed
that, similar to the Bacteria and Eukarya,
the archaeal domain of life might harbor
certain species capable of causing disease
(Cavicchioli et al., 2003; Eckburg et al.,
2003). Now, a decade later, it is time to
revisit the topic in the light of new data
available. The last decade witnessed a mas-
sive use of molecular ecology tools in clin-
ical microbiology, and these data can be
inspected for the potential involvement of
the Archaea in various infectious diseases
in humans and animals.
Unlike the Bacteria, the diversity of the
Archaea in the human body is substantially
lower, including representatives of only
one phylum, Euryarchaeota. The phylum
includes three species: Methanobrevibacter
smithii, foundmostly in the gut and vagina
(Miller and Wolin, 1982; Belay et al.,
1990); Methanosphaera stadtmanae, found
mostly in the gut (Miller andWolin, 1985);
and M. oralis, found mostly in the oral
cavity (Belay et al., 1988; Ferrari et al.,
1994). Compared to bacteria, the relative
abundance of archaea is also much lower
(Miller and Wolin, 1982), although the
recent improvements in cultivation and
DNA detection may help to estimate these
numbers more accurately (Dridi et al.,
2009; Khelaifia et al., 2013).
The first work suggesting an associ-
ation of the Archaea with human gas-
trointestinal disease was published in 1985
(McKay et al., 1985). Patients with Crohn’s
disease, ulcerative colitis and primary
pneumatosis intestinalis displayed a signif-
icantly lower incidence of methane excre-
tion compared to healthy subjects. On
the contrary, patients with diverticulosis
showed a significantly increased inci-
dence of methanogens compared to con-
trol (Weaver et al., 1986). Since then,
there have been a number of studies,
with more recent ones using molecular
ecology markers, such as the 16S rRNA
and mcrA genes, which have confirmed
these two initial observations. That is, in
conditions characterized by extended tran-
sit time in the intestine, the incidence,
and rate of methane production are higher
(Fiedorek et al., 1990; Pimentel et al., 2003;
Chatterjee et al., 2007), while the diar-
rheal conditions of human gastrointestinal
disease result in the opposite trend with
lower incidences of methanogenic archaea
and lower rates of methane production
(McKay et al., 1985; Scanlan et al., 2008).
Chemotherapy-induced diarrhea in cancer
patients has also resulted in the decrease
of methanogenic archaea in parallel with
the loss of beneficial bacteria (Stringer
et al., 2013). Indeed, experimental inter-
ventions to increase the intestinal transit
rate have resulted in the decline of fecal
methanogens and methane production,
while the opposite effect has been observed
in the loperamide treatment group (Lewis
and Cochrane, 2007).
Recent reassessments of the role of
methane production among patients with
gastrointestinal disturbances have clearly
associated elevated methane production
with alterations in intestinal motility, such
as constipation, but not with other con-
ditions (Attaluri et al., 2010; Furnari
et al., 2012). Thus, a pathogenic link with
methanogens is unlikely (Di Stefano and
Corazza, 2010), and their involvement in
gastrointestinal disease is presently uncor-
roborated. From the ecological/system
biology viewpoint the numbers and the
methane production by archaea is more
likely a reflection of syntrophic relation-
ships in the gut where the local envi-
ronment, depending on a number of
factors, may favor hydrogen channeling
through alternative mechanisms of hydro-
gen disposal, such as methanogenesis, sul-
fate reduction, or acetogenesis. In this
regard, alternative generation of highly
toxic hydrogen sulfide as a result of sulfate
reduction in the gut may impose much
higher health risks (Medani et al., 2011;
Carbonero et al., 2012) compared to more
inert methane.
The best-studied cases of a potential
involvement of the Archaea in human
pathology, however, are linked to peri-
odontal disease.Methanobrevibacter oralis-
like phylotypes, for example, have been
detected by PCR in up to 36% of peri-
odontitis patients (Lepp et al., 2004).
In another study, five cases of apical
periodontitis out of 20 total have been
found positive for the Archaea (Vianna
et al., 2006). The follow up work by
the same group has greatly contributed
to our understanding of the role played
by hydrogenotrophic microorganisms in
periodontal disease (Vianna et al., 2008).
Compared to periodontitis patients, the
supragingival plaque of healthy subjects
harbors a lower total microbial load,
and the hydrogenotrophic group is repre-
sented exclusively by acetogenic bacteria,
also at lower numbers. On the contrary,
the subgingival plaque from periodonti-
tis patients harbors a larger number of
total bacteria, and the hydrogenotrophic
group includes methanogenic archaea and
sulphate-reducing bacteria (SRB) in addi-
tion to acetogenic bacteria. The latter two
groups are absent in healthy control sub-
jects but present in 65% of periodontitis
patients, alone or in combination (Vianna
et al., 2008).
It needs to be noted here that the
presence of SRB in human saliva can be
detected in 30% of subjects and, among
other oral and systemic conditions, the
only statistically significant association
of the SRB carriage is with periodonti-
tis (Heggendorn et al., 2013). Although
the proportion of hydrogenotrophs in
periodontal disease is below 1% of the
total microbiota (Vianna et al., 2008),
the hydrogen sink they provide may
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create a favorable microenvironment
for the microbial consortium, espe-
cially for the proliferation of a keystone
periodontal pathogen, Porphyromonas
gingivalis, which is capable of inducing
host responses that ultimately result in
uncontrolled inflammation and tissue
damage (Hajishengallis et al., 2012).
Thus, the role of the Archaea in
periodontal disease cannot be construed
within the frames of a typical host-
pathogen interaction, and we have to
acknowledge that these are not bona
fide pathogens. Their involvement in
disease can still be interpreted from
the point of view of polymicrobial dis-
eases that has recently gained consid-
erable attention (Peters et al., 2012).
The diseases involve complex microbial
communities instead of clear-cut cases
of monocultural infections by classical
pathogens.
The fine-tuned host-microbe interac-
tion that has been evolving during the
long co-evolutionary adaptations of both
sides to one another is largely mutual
but can be compromised due to genetic
defects and/or environmental factors
(Khachatryan et al., 2008; Littman and
Pamer, 2011). Because of amalfunctioning
interface, a subset of normally symbi-
otic bacteria could display potentially
pathogenic properties; they thus have been
called “pathobionts” to be differentiated
from the “classical,” acquired or oppor-
tunistic pathogens (Chow et al., 2011).
Can then the commensal methanogenic
Archaea be considered as “pathobionts”?
Pathogenic potential of pathobionts is
expressed under certain circumstances,
such as in a genetically susceptible host
(Chow et al., 2011), and recent analyses
have indeed found a significant associa-
tion between IL-10 polymorphisms and
periodontitis (Albuquerque et al., 2012;
Atanasovska-Stojanovska et al., 2012;
Zhong et al., 2012). A broader genome-
wide association study, however, failed
to detect any significant association of
genetic polymorphisms with periodontitis
diagnosis (Divaris et al., 2012). Suggestive
evidence of association has been obtained
for 13 loci and 8 periodontal pathogens
from the previously defined “red” and
“orange” clusters (Socransky et al., 2004).
As for the methanogen carriage, a study
of monozygotic and dizygotic twins found
no link between the host genetics and the
occurrence of methanogenic microbiota
(Florin et al., 2000).
In a “classical” pathogen situation a
taxonomic signature of it is sufficient to
deduce its identity and associated etiology
of a disease. In polymicrobial diseases,
such as periodontitis, however, taxonomic
signatures are less efficacious as disease
predictors, although some attempts are
being made to identify the key players
within certain pathobiota (Hajishengallis
et al., 2012). Still, the keystone pathogens
rely on the community to realize the full
pathogenic potential, and the hydrogen
sink appears to be important for the peri-
odontal disease progression. The role of
hydrogenotrophic microbiota in this pro-
cess is interchangeable and can be played
by SRB, methanogenic archaea, or ace-
togenic bacteria (Vianna et al., 2008).
Formation of microbiota with the preva-
lence of one of these hydrogenotrophic
groups may happen by chance. For exam-
ple, the proportion of periodontal disease
cases involving methanogenic archaea at
36% (Lepp et al., 2004) is very similar
to the proportion of methane producers
in a general population, which remains
very stable over a 35-year period despite
the extensive use of antibiotics and dietary
changes (33.6–36.4%) (Levitt et al., 2006).
A similar link may exist between the fre-
quency of SRB in periodontal disease and
the general occurrence and prevalence of
SRB on other body sites. These hypothe-
ses are worth testing to potentially provide
a simple mechanistic explanation for the
occurrence and frequency of methanogens
and SRBs as hydrogenotrophic microor-
ganisms in periodontitis.
Comparison of metagenomes of
healthy and diseased microbiota may
help to identify the sets of genes differen-
tially represented in these two conditions
and point to the enrichment or reduc-
tion of genes specific for pathologies.
Signatures of periodontal disease point
to the enrichment by genes encoding
metabolic functions that are consistent
with a parasitic lifestyle and anaerobic
metabolism, as well as by genes encoding
virulence factors and the biosynthesis of
toxic factors (Liu et al., 2012; Wang et al.,
2013). The shift of the subgingival crevice
microbiota to the anaerobic type in disease
may facilitate the colonization of this niche
by hydrogenotrophic microorganisms
from other body sites in the corresponding
carriers.
Another important factor involved in
the disease is the host response, which
is realized via the host-microbe interface
(Armitage, 2013; Bartold and Van Dyke,
2013). More facts are emerging support-
ing the view that one of the primary causes
of the disease is the inappropriate host
response to the microbiota leading to tis-
sue changes at the initial gingivitis stage.
This altered microenvironment affects the
composition of local microbiota, shift-
ing it to the pathobiota, and contributes
to the subsequent development of peri-
odontitis, if the genetic and environmental
factors are conducive for disease develop-
ment (Bartold and Van Dyke, 2013). The
host mechanisms involved in this destruc-
tive process can be switched off in ani-
mal models of periodontitis, which result
in drastic improvement of clinical pre-
sentation. For example, RNAi-mediated
silencing of Atp6i prevents bone loss and
inflammation in the mouse model of peri-
odontal disease (Jiang et al., 2013) and in
the mouse model of endodontic disease
(Ma et al., 2013). Silencing of cathepsin
K in periapical tissues can significantly
reduce endodontic disease development,
bone destruction and inflammation in
a mouse disease model (Gao et al.,
2013). Periodontitis, therefore, is provoked
by the excessive host’s proinflammatory
responses to the microbiota during the
early stages of disease development, thus
changing the microenvironment and cre-
ating novel niche opportunities (Bartold
and Van Dyke, 2013), which are promptly
used by a number of microorganisms,
including the Archaea.
The involvement of cell-mediated
immunity in periodontal disease has
been first demonstrated more than 40
years ago (Ivanyi et al., 1972). Since
then, the idea that the development of
periodontal disease with the resulting
connective tissue breakdown involves
inappropriate host responses has been
gaining a widespread acceptance, espe-
cially following the discovery of the host
modulating properties of minocycline
30 years ago (Golub et al., 1983). This
effect is based on inhibition of certain
host metal matrix metalloproteinases
(MMPs) by low-dose tetracyclines; this
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type of treatment is approved by the FDA
and other national regulatory agencies in
Canada and Europe for the management
of chronic periodontal disease (Gu et al.,
2012). Current preventive and treatment
approaches, however, are only partially
effective because of the focus on biofilm
management (Tonetti et al., 2011). Better
understanding of host modulation and
inflammation resolution is necessary to
develop new, more effective, and effi-
cient preventive and treatment approaches
(Tonetti et al., 2011).
But why the disease is so widespread?
Have the host responses toward the oral
microbiota always been so destructive?
These questions can be answered through
the prism of dietary and cultural changes
in human history. Two major changes
in the diet, i.e. the carbohydrate-rich
Neolithic with the introduction of farming
(∼10,000 years ago) and the more recent
advent of industrially-processed flour and
sugar (in ∼1850), shifted the oral micro-
bial community to a disease-associated
configuration (Adler et al., 2013). Thus,
the host-microbe equilibrium that had
evolved as a result of previous long-
term co-evolution has been jeopardized
by the diet-affected and less stable and
diverse microbiota, with presumably less
appropriate functional and signaling prop-
erties. This has probably been the key
event that continues to incite exagger-
ated host immune responses leading to
the disease.
Currently, there is no substantial
evidence supporting the pathogenic prop-
erties of the Archaea. The best they can
do is to cease the opportunity created
by pathological processes and occupy
the microenvironments suitable for this
type of anaerobic hydrogenotrophic
metabolism. These niches, however, can
also be occupied by other microbiota with
similar metabolic properties.
REFERENCES
Adler, C. J., Dobney, K., Weyrich, L. S., Kaidonis, J.,
Walker, A. W., Haak, W., et al. (2013). Sequencing
ancient calcified dental plaque shows changes
in oral microbiota with dietary shifts of the
neolithic and industrial revolutions. Nat. Genet.
45, 450–455. doi: 10.1038/ng.2536
Albuquerque, C. M., Cortinhas, A. J., Morinha, F.
J., Leitão, J. C., Viegas, C. A., and Bastos, E. M.
(2012). Association of the IL-10 polymorphisms
and periodontitis: a meta-analysis. Mol. Biol. Rep.
39, 9319–9329. doi: 10.1007/s11033-012-1738-1
Armitage, G. C. (2013). Learned and unlearned
concepts in periodontal diagnostics: a 50-year
perspective. Periodontol. 2000, 62, 20–36. doi:
10.1111/prd.12006
Atanasovska-Stojanovska, A., Trajkov, D., Popovska,
M., and Spiroski, M. (2012). IL10 -1082, IL10
-819 and IL10 -592 polymorphisms are associ-
ated with chronic periodontitis in a Macedonian
population. Hum. Immunol. 73, 753–758. doi:
10.1016/j.humimm.2012.04.009
Attaluri, A., Jackson, M., Valestin, J., and Rao,
S. S. (2010). Methanogenic flora is associated
with altered colonic transit but not stool char-
acteristics in constipation without IBS. Am.
J. Gastroenterol. 105, 1407–1411. doi: 10.1038/
ajg.2009.655
Bartold, P. M., and Van Dyke, T. E. (2013).
Periodontitis: a host-mediated disruption of
microbial homeostasis. Unlearning learned
concepts. Periodontol. 2000, 62, 203–217. doi:
10.1111/j.1600-0757.2012.00450.x
Belay, N., Johnson, R., Rajagopal, B. S., Conway de
Macario, E., and Daniels, L. (1988). Methanogenic
bacteria from human dental plaque. Appl. Environ.
Microbiol. 54, 600–603.
Belay, N., Mukhopadhyay, B., Conway de
Macario, E., Galask, R., and Daniels, L.
(1990). Methanogenic bacteria in human
vaginal samples. J. Clin. Microbiol. 28,
1666–1668.
Carbonero, F., Benefiel, A. C., Alizadeh-Ghamsari, A.
H., and Gaskins, H. R. (2012). Microbial path-
ways in colonic sulfur metabolism and links with
health and disease. Front. Physiol. 3:448. doi:
10.3389/fphys.2012.00448
Cavicchioli, R., Curmi, P. M., Saunders, N.,
and Thomas, T. (2003). Pathogenic archaea:
do they exist? Bioessays 25, 1119–1128. doi:
10.1002/bies.10354
Chatterjee, S., Park, S., Low, K., Kong, Y., and
Pimentel, M. (2007). The degree of breath
methane production in IBS correlates with the
severity of constipation. Am. J. Gastroent. 102,
837–841. doi: 10.1111/j.1572-0241.2007.01072.x
Chow, J., Tang, H., and Mazmanian, K. S. (2011).
Pathobionts of the gastrointestinal microbiota and
inflammatory disease. Curr. Opin. Immunol. 23,
473–480. doi: 10.1016/j.coi.2011.07.010
Di Stefano, M., and Corazza, G. R. (2010).
Methanogenic flora and constipation:
many doubts for a pathogenetic link.
Am. J. Gastroenterol. 105, 2304–2305. doi:
10.1038/ajg.2010.282
Divaris, K., Monda, K. L., North, K. E., Olshan, A. F.,
Lange, E. M., Moss, K., et al. (2012). Genome-wide
association study of periodontal pathogen colo-
nization. J. Dent. Res. 91(Suppl. 7), 21S–28S. doi:
10.1177/0022034512447951
Dridi, B., Henry, M., El Khéchine, A., Raoult,
D., and Drancourt, M. (2009). High preva-
lence of Methanobrevibacter smithii and
Methanosphaera stadtmanae detected in the
human gut using an improved DNA detection
protocol. PLoS ONE 4:e7063. doi: 10.1371/
journal.pone.0007063
Eckburg, P. B., Lepp, P. W., and Relman, D.
A. (2003). Archaea and their potential role in
human disease. Infect. Immun. 71, 591–596. doi:
10.1128/IAI.71.2.591-596.2003
Ferrari, A., Brusa, T., Rutili, A., Canzi, E., and
Biavati, B. (1994). Isolation and characterization
Methanobrevibacter oralis sp. nov. Curr Microbiol.
6, 7–12.
Fiedorek, S. C., Pumphrey, C. L., and Casteel,
H. B. (1990). Breath methane production in
children with constipation and encopresis.
J. Pediatr. Gastroenterol. Nutr. 10, 473–477. doi:
10.1097/00005176-199005000-00010
Florin, T. H., Zhu, G., Kirk, K. M., and Martin, N. G.
(2000). Shared and unique environmental factors
determine the ecology of methanogens in humans
and rats. Am. J. Gastroenterol. 95, 2872–2879. doi:
10.1111/j.1572-0241.2000.02319.x
Furnari, M., Savarino, E., Bruzzone, L., Moscatelli,
A., Gemignani, L., Giannini, E. G., et al. (2012).
Reassessment of the role of methane produc-
tion between irritable bowel syndrome and func-
tional constipation. J. Gastrointestin. Liver Dis. 21,
157–163.
Gao, B., Chen, W., Hao, L., Zhu, G., Feng, S., Ci,
H., et al. (2013). Inhibiting periapical lesions
through AAV-RNAi silencing of cathepsin K.
J. Dent. Res. 92, 180–186. doi: 10.1177/00220345
12468757
Golub, L. M., Lee, H. M., Lehrer, G., Nemiroff,
A., McNamara, T. F., Kaplan, R., et al. (1983).
Minocycline reduces gingival collagenolytic
activity during diabetes. Preliminary obser-
vations and a proposed new mechanism of
action. J. Periodontal. Res. 18, 516–526. doi:
10.1111/j.1600-0765.1983.tb00388.x
Gu, Y., Walker, C., Ryan, M. E., Payne, J. B., and
Golub, L. M. (2012). Non-antibacterial tetracy-
cline formulations: clinical applications in den-
tistry and medicine. J. Oral. Microbiol. 4. doi:
10.3402/jom.v4i0.19227
Hajishengallis, G., Darveau, R. P., and Curtis, M. A.
(2012). The keystone-pathogen hypothesis. Nat.
Rev. Microbiol. 10, 717–725. doi: 10.1038/nrmi-
cro2873
Heggendorn, F. L., Souza Gonçalves, L., Dias, E. P.,
Silva Junior, A., Galvão, M. M., and Lutterbach,
M. T. (2013). Detection of sulphate-reducing
bacteria in human saliva. Acta Odontol. Scand.
doi: 10.3109/00016357.2013.770163. [Epub ahead
of print].
Ivanyi, L. M., Wilton, J. M. A., and Lehner, T. (1972).
Cell-mediated immunity in periodontal disease;
cytotoxicity, migration inhibition and lympho-
cyte transformation studies. Immunology 22,
141–145.
Jiang, H., Chen, W., Zhu, G., Zhang, L., Tucker, B.,
Hao, L., et al. (2013). RNAi-mediated silencing of
Atp6i and Atp6i haploinsufficiency prevents both
bone loss and inflammation in a mouse model
of periodontal disease. PLoS ONE 8:e58599. doi:
10.1371/journal.pone.0058599
Khachatryan, Z. A., Ktsoyan, Z. A., Manukyan, G.
P., Kelly, D., Ghazaryan, K. A., and Aminov, R. I.
(2008). Predominant role of host genetics in con-
trolling the composition of gut microbiota. PLoS
ONE 3:e3064. doi: 10.1371/journal.pone.0003064
Khelaifia, S., Raoult, D., and Drancourt, M. (2013).
A versatile medium for cultivating methanogenic
archaea. PLoS ONE 8:e61563. doi: 10.1371/jour-
nal.pone.0061563
Lepp, P. W., Brinig, M. M., Ouverney, C. C., Palm,
K., Armitage, G. C., Relman, D. A. (2004).
Frontiers in Cellular and Infection Microbiology www.frontiersin.org August 2013 | Volume 3 | Article 42 | 3
Aminov Role of archaea in human disease
Methanogenic Archaea and human periodon-
tal disease. Proc. Natl. Acad. Sci. U.S.A. 101,
6176–6181. doi: 10.1073/pnas.0308766101
Levitt, M. D., Furne, J. K., Kuskowski, M., and
Ruddy, J. (2006). Stability of human methanogenic
flora over 35 years and a review of insights
obtained from breath methane measurements.
Clin. Gastroenterol. Hepatol. 4, 123–129. doi:
10.1016/j.cgh.2005.11.006
Lewis, S., and Cochrane, S. (2007). Alteration of
sulfate and hydrogen metabolism in the human
colon by changing intestinal transit rate. Am. J.
Gastroenterol. 102, 624–633. doi: 10.1111/j.1572-
0241.2006.01020.x
Littman, D. R., and Pamer, E. G. (2011). Role of the
commensal microbiota in normal and pathogenic
host immune responses. Cell Host Microbe 10,
311–323. doi: 10.1016/j.chom.2011.10.004
Liu, B., Faller, L. L., Klitgord, N., Mazumdar,
V., Ghodsi, M., Sommer, D. D., et al. (2012).
Deep sequencing of the oral microbiome reveals
signatures of periodontal disease. PLoS ONE
7:e37919. doi: 10.1371/journal.pone.0037919
Ma, J., Chen,W., Zhang, L., Tucker, B., Zhu, G., Sasaki,
H., et al. (2013). RNA interference-mediated
silencing of Atp6i prevents both periapical bone
erosion and inflammation in the mouse model of
endodontic disease. Infect. Immun. 81, 1021–1030.
doi: 10.1128/IAI.00756-12
McKay, L. F., Eastwood, M. A., and Brydon, W. G.
(1985). Methane excretion in man – a study of
breath, flatus, and faeces. Gut 26, 69–74. doi:
10.1136/gut.26.1.69
Medani, M., Collins, D., Docherty, N. G., Baird,
A. W., O’Connell, P. R., and Winter, D. C.
(2011). Emerging role of hydrogen sulfide
in colonic physiology and pathophysiology.
Inflamm. Bowel Dis. 17, 1620–1625. doi: 10.1002/
ibd.21528
Miller, T. L., and Wolin, M. J. (1982). Enumeration
of Methanobrevibacter smithii in human feces.
Arch. Microbiol. 131, 14–18. doi: 10.1007/
BF00451492
Miller, T. L., and Wolin, M. J. (1985).Methanosphaera
stadtmaniae gen. nov., sp. nov.: a species that
forms methane by reducing methanol with
hydrogen. Arch. Microbiol. 141, 116–122. doi:
10.1007/BF00423270
Peters, B. M., Jabra-Rizk, M. A., O’May, G. A.,
Costerton, J. W., and Shirtliff, M. E. (2012).
Polymicrobial interactions: impact on pathogen-
esis and human disease. Clin. Microbiol. Rev. 25,
193–213. doi: 10.1128/CMR.00013-11
Pimentel, M., Mayer, A. G., Park, S., Chow, E.
J., Hasan, A., and Kong, Y. (2003). Methane
production during lactulose breath test
is associated with gastrointestinal disease
presentation. Dig. Dis. Sci. 48, 86–92. doi:
10.1023/A:1021738515885
Scanlan, P. D., Shanahan, F., and Marchesi, J. R.
(2008). Human methanogen diversity and inci-
dence in healthy and diseased colonic groups using
mcrA gene analysis. BMC Microbiol. 8:79. doi:
10.1186/1471-2180-8-79
Socransky, S. S., Haffajee, A. D., Smith, C., Martin,
L., Haffajee, J. A., Uzel, N. G., et al. (2004).
Use of checkerboard DNA-DNA hybridiza-
tion to study complex microbial ecosystems.
Oral. Microbiol. Immunol. 19, 352–362. doi:
10.1111/j.1399-302x.2004.00168.x
Stringer, A. M., Al-Dasooqi, N., Bowen, J. M., Tan,
T. H., Radzuan, M., Logan, R. M., et al. (2013).
Biomarkers of chemotherapy-induced diarrhea: a
clinical study of intestinal microbiome alterations,
inflammation and circulating matrix metallopro-
teinases. Support. Care Cancer 21, 1843–1852. doi:
10.1007/s00520-013-1741-7
Tonetti, M. S., Chapple, I. L., andWorking Group 3 of
Seventh European Workshop on Periodontology.
(2011). Biological approaches to the development
of novel periodontal therapies–consensus of the
Seventh European Workshop on Periodontology.
J. Clin. Periodontol. 38(Suppl. 11), 114–118. doi:
10.1111/j.1600-051X.2010.01675.x
Vianna, M. E., Conrads, G., Gomes, B. P. F. A., and
Horz, H. P. (2006). Identification and quantifica-
tion of archaea involved in primary endodontic
infections. J. Clin. Microbiol. 44, 1274–1282. doi:
10.1128/JCM.44.4.1274-1282.2006
Vianna, M. E., Holtgraewe, S., Seyfarth, I., Conrads,
G., and Horz, H. P. (2008). Quantitative
analysis of three hydrogenotrophic microbial
groups, methanogenic archaea, sulfate-reducing
bacteria, and acetogenic bacteria, within plaque
biofilms associated with human periodon-
tal disease. J. Bacteriol. 190, 3779–3785. doi:
10.1128/JB.01861-07
Wang, J., Qi, J., Zhao, H., He, S., Zhang, Y., Wei,
S., et al. (2013). Metagenomic sequencing reveals
microbiota and its functional potential associated
with periodontal disease. Sci. Rep. 3, 1843. doi:
10.1038/srep01843
Weaver, G. A., Krause, J. A., Miller, T. L., and Wolin,
M. J. (1986). Incidence of methanogenic bacteria
in a sigmoidoscopy population, an association of
methanogenic bacteria and diverticulosis. Gut 27,
698–704. doi: 10.1136/gut.27.6.698
Zhong, Q., Ding, C., Wang, M., Sun, Y., and
Xu, Y. (2012). Interleukin-10 gene polymor-
phisms and chronic/aggressive periodontitis
susceptibility: a meta-analysis based on 14
case-control studies. Cytokine 60, 47–54. doi:
10.1016/j.cyto.2012.05.014
Received: 13 June 2013; accepted: 26 July 2013;
published online: 13 August 2013.
Citation: Aminov RI (2013) Role of archaea in human
disease. Front. Cell. Infect. Microbiol. 3:42. doi: 10.3389/
fcimb.2013.00042
Copyright © 2013 Aminov. This is an open-access arti-
cle distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the
original publication in this journal is cited, in accor-
dance with accepted academic practice. No use, distribu-
tion or reproduction is permitted which does not comply
with these terms.
Frontiers in Cellular and Infection Microbiology www.frontiersin.org August 2013 | Volume 3 | Article 42 | 4
